Neetika Sharma*

Department of Neurology, AIIMS Bilaspur, India

*Corresponding Author: Neetika Sharma, Department of Neurology, AIIMS Bilaspur, India.

Received: September 16, 2024; Published: October 30, 2024

Abstract

Acute flaccid myelitis is an asymmetric flaccid weakness of one or all four limbs preceded by a prodrome of fever with respiratory or gastrointestinal illness. Typically affecting healthy children, with a higher incidence in males, these cases often occur in clusters following Enterovirus outbreaks. While primarily documented in the United States, they have been reported worldwide. Acute flaccid myelitis has affected a vast majority of children leaving them with crippling disability. It has become a notifiable disease per the Centre for Disease Control and Prevention. This review focuses on the need for more research in this field as till now no definitive treatment is present. Literature is lacking in its management. Currently, only available treatment options include intravenous immunoglobulin. The role of steroids is controversial. As there are both beneficial and harmful effects of steroids have been reported.

Acute illness is followed by either recovery or complications involving musculoskeletal deformities, pressure ulcers, and aspiration pneumonia in patients with bulbar involvement. We need more studies and research focusing on its therapeutics which could prove life-saving and prevent morbidity in the coming future.

 Keywords: Myelitis; Neuromuscular Disorder; Enterovirus Outbreak; Central Nervous System Viral infections; CDC Recommendations

References

1. Ide W., et al. “Acute Flaccid Myelitis”. Physical Medicine and Rehabilitation Clinics of North America 3 (2021): 477-491.
2. Hardy D and Hopkins S. “Update on acute flaccid myelitis: recognition, reporting, etiology, and outcomes”. Archives of Disease in Childhood (2020).
3. Center for Disease Control and Prevention, (CDC). “Acute flaccid myelitis: Case definition for AFM”.
4. Murphy OC., et al. “Acute flaccid myelitis: cause, diagnosis, and management”. Lancet London England10271 (2021): 334-346.
5. Dinov D and Donowitz JR. “Acute flaccid myelitis a review of the literature”. Frontiers in Neurology 13 (2022): 1034607.
6. Kramer R., et al. “Acute flaccid myelitis caused by enterovirus D68: Case definitions for use in clinical practice”. European Journal of Paediatric Neurology 2 (2019): 235-239.
7. Vogt MR., et al. “Enterovirus D68 in the anterior horn cells of a child with acute flaccid myelitis”. New England Journal of Medicine 386 (2022): 2059-2060.
8. Fang X and Huda R. “Acute Flaccid Myelitis: Current Status and Diagnostic Challenges”. Journal of Clinical Neurology 3 (2020): 376-382.
9. McLaren N., et al. “Characteristics of patients with acute flaccid myelitis, United States, 2015-2018”. Emerging Infectious Diseases 26 (2020): 212-219.
10. Murphy OC and Pardo CA. “Acute Flaccid Myelitis: A Clinical Review”. Seminars in Neurology 2 (2020): 211-218.
11. Aliabadi N., et al. “Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014”. Emerging Infectious Diseases 08 (2016): 1387-1394.
12. Ayers T., et al. “Acute Flaccid Myelitis in the United States: 2015-2017”. Pediatrics5 (2019): e20191619.
13. Lopez A., et al. “Vital Signs: Surveillance for Acute Flaccid Myelitis - United States, 2018”. Morbidity and Mortality Weekly Report p27 (2019): 608-614.
14. Fatemi Y and Chakraborty R. “Acute Flaccid Myelitis: A Clinical Overview for 2019”. Mayo Clinic Proceedings5 (2019): 875-881.
15. Van Haren K., et al. “Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015”. JAMA 24 (2015): 2663-2671.
16. Helfferich Jelte., et al. “Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019”. Eurosurveillance42 (2022): pii=2200157.
17. Midgley CM., et al. “Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation”. The Lancet Respiratory Medicine 3 (2015): 879-887.
18. Kramer R., et al. “Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016”. Eurosurveillance 23 (2018): 1700711.
19. Menant JC and Gandevia SC. “Poliomyelitis. In: Day BL, Lord SR, eds. Handbook of clinical neurology. Netherlands: Elsevier Health Sciences (2018): 337-344.
20. Chang LY., et al. “Enterovirus A71 neurologic complications and longterm sequelae”. Journal of Biomedical Science 26 (2019): 57.
21. Bodian D. “Histopathologic basis of clinical findings in poliomyelitis”. The American Journal of Medicine 6 (1949): 563-578.
22. Cusick MF., et al. “Molecular mimicry as a mechanism of autoimmune disease”. Clinical Reviews in Allergy and Immunology 1 (2012): 102-111.
23. Vawter-Lee M., et al. “Acute Flaccid Myelitis: A Multidisciplinary Protocol to Optimize Diagnosis and Evaluation”. Journal of Child Neurology 6 (2021): 421-431.
24. Board of Scientific Counselors. National overview of acute flaccid myelitis-United States, 2014-2018 (2018).
25. Messacar K., et al. “A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA”. Lancet9978 (2015): 1662-1671.
26. Helfferich J., et al. “Acute flaccid myelitis and enterovirus D68: lessons from the past and present”. European Journal of Pediatrics 78 (2019): 1305-1315.
27. Chong PF., et al. “Clinical features of acute flaccid myelitis temporally associated with an enterovirus D68 outbreak: results of a nationwide survey of acute flaccid paralysis in Japan, August-December 2015”. Clinical Infectious Diseases 66 (2018): 653-664.
28. Theroux LM and Brenton JN. “Acute transverse and flaccid myelitis in children”. Current Treatment Options in Neurology 12 (2019): 64.
29. Hopkins SE., et al. “Acute Flaccid Myelitis-Keys to Diagnosis, Questions About Treatment, and Future Directions”. JAMA Pediatrics 2 (2019): 117-118.
30. Jorba J., et al. “Update on vaccine derived poliovirus outbreak- worldwide, January- June 2019”.
    Morbidity and Mortality Weekly Report 45 (2019): 1024.
31. Gordon-Lipkin E., et al. “Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease”. Developmental Medicine and Child Neurology 61 (2019): 366-375.
32. Okumura A., et al. “Serial MRI findings of acute flaccid myelitis during an outbreak of enterovirus D68 infection in Japan”. Brain and Development 41 (2019): 443-451.
33. Maloney JA., et al. “MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak”. American Journal of Neuroradiology 36 (2015): 245-250.
34. Chong PF., et al. “Acute flaccid myelitis with neuroradiological finding of brachial plexus swelling”. Pediatric Neurology 109 (2020): 85-88.
35. Elrick MJ., et al. “Clinical subpopulations in a sample of north American children diagnosed with acute flaccid myelitis, 2012-2016”. JAMA Pediatrics 173 (2019): 134-139.
36. Waters PJ., et al. “Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays”. Neurology 78 (2012): 665-671.
37. McKeon A., et al. “Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays”. Archives of Neurology 66 (2009): 1134-1138.
38. Matà S., et al. “Motor nerve damage is associated with antiganglioside antibodies in diabetes”. Journal of the Peripheral Nervous System 9 (2004): 138-143.
39. Van Haren K., et al. “Acute flaccid myelitis of unknown etiology in California, 2012-2015”. JAMA 314 (2015): 2663-2671.
40. Hovden IAH and Pfeiffer HCV. “Electrodiagnostic findings in acute flaccid myelitis related to enterovirus D68”. Muscle Nerve 52 (2015): 909-910.
41. Knoester M., et al. “Twenty-nine cases of enterovirus-D68-associated acute flaccid myelitis in europe 2016: a case series and epidemiologic overview”. The Pediatric Infectious Disease Journal 38 (2019): 16-21.
42. Elrick MJ., et al. “Clinical subpopulations in a sample of north American children diagnosed with acute flaccid myelitis, 2012-2016”. JAMA Pediatrics 173 (2019): 134-139.
43. Hixon AM., et al. “Evaluating treatment efficacy in a mouse model of enterovirus D68-associated paralytic myelitis”. The Journal of Infectious Diseases 216 (2017): 1245-1253.
44. Zhang Y., et al. “Neutralization of enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products”. Journal of Clinical Virology 69 (2015): 172-175.
45. Rhoden E., et al. “In vitro efficacy of antiviral compounds against enterovirus D68”. Antimicrobial Agents and Chemotherapy 59 (2015): 7779-7781.
46. Shen FH., et al. “Early dexamethasone treatment exacerbates enterovirus 71 infection in mice”. Virology 5 (2014): 218-227.
47. Kirolos A., et al. “Outcome of paediatric acute flaccid myelitis associated with enterovirus D68: a case series”. Developmental Medicine and Child Neurology 61 (2019): 376-380.
48. Nelson GR., et al. “Recognition and management of acute flaccid myelitis in children”. Pediatric Neurology 55 (2019): 17-21.
49. Knoester M., et al. “Twenty-nine cases of enterovirus-D68-associated acute flaccid Myelitis in Europe 2016: a case series and epidemiologic overview”. The Pediatric Infectious Disease Journal 38 (2019): 16-21.
50. Zheng Q., et al. “Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization”. Nature Microbiology 1 (2019): 124-133.
51. Dai W., et al. “A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice”. Vaccine 5 (2018): 653-659.
52. Christy A and Messacar K. “Acute Flaccid Myelitis Associated with Enterovirus D68: A Review”. Journal of Child Neurology 9 (2019): 511-516.
53. Melicosta ME., et al. “Acute flaccid myelitis: rehabilitation challenges and outcomes in a pediatric cohort”. Journal of Pediatric Rehabilitation Medicine 3 (2019): 245-253.
54. Pino PA., et al. “Early results of nerve transfers for restoring function in severe cases of acute flaccid myelitis”. Annals of Neurology 4 (2019): 607-615.
55. Moore AM., et al. “Lower extremity nerve transfers in acute flaccid myelitis patients: a case series. Plastic and Reconstructive Surgery - Global Open 9 (2021): e3699.
56. Willison HJ., et al. “Guillain-Barré syndrome”. Lancet 388 (2016): 717-727.
57. Elrick MJ., et al. “Clinical subpopulations in a sample of north American children diagnosed with acute flaccid myelitis, 2012-2016”. JAMA Pediatrics 173 (2019): 134-139.
58. World Health Organization. Global polio eradication initiative (2020).
59. Turtle L and Solomon T. “Japanese encephalitis - the prospects for new treatments”. Nature Reviews Neurology 14 (2018): 298-313.
60. Sejvar JJ. “Clinical manifestations and outcomes of West Nile virus infection”. Viruses 6 (2014): 606-623.
61. Lindquist L and Vapalahti O. “Tick-borne encephalitis”. Lancet 371 (2008): 1861-1871.
62. Seeliger T., et al. “Neuro-Sjögren: peripheral neuropathy With limb weakness in Sjögren's syndrome”. Frontiers in Immunology 10 (2019): 1600.
63. Martin JA., et al. “Outcomes of Colorado children with acute flaccid myelitis at 1 year”. Neurology 89 (2017): 129-117.
64. McCoy DB., et al. “MRI atlas-based measurement of spinal cord injury predicts outcome in acute flaccid myelitis”. American Journal of Neuroradiology 38 (2017): 410-417.
65. Martin JA., et al. “Outcomes of Colorado children with acute flaccid myelitis at 1 year”. Neurology 89 (2017).
66. Melicosta ME., et al. “Acute flaccid myelitis: rehabilitation challenges and outcomes in a pediatric cohort”. Journal of Pediatric Rehabilitation Medicine 12 (2019): 245-253.
67. Saltzman EB., et al. “Nerve transfers for enterovirus D68-associated acute flaccid myelitis: a case series”. Pediatric Neurology 88 (2018): 25-30.
68. Doi K., et al. “Surgical reconstruction for upper-extremity paralysis following acute flaccid myelitis”. JB JS Open Access 4 (2019): e0030.
69. Edmiston TL., et al. “Early use of an implantable diaphragm pacing stimulator for a child with severe acute flaccid myelitis-a case report”. Spinal Cord Series and Cases 5 (2019): 67.
70. Bove R., et al. “Unmet needs in the evaluation, treatment, and recovery for 167 children affected by acute flaccid myelitis reported by parents through social media”. Pediatric Neurology 102 (2020): 20-27.
71. Yea C., et al. “Longitudinal outcomes in the 2014 acute flaccid paralysis cluster in Canada”. Journal of Child Neurology 32 (2017): 301-307.
72. Dahan V., et al. “Sleep-disordered breathing in fatigued postpoliomyelitis clinic patients”. Archives of Physical Medicine and Rehabilitation 87 (2006): 1352-1356.
73. Kay L., et al. “Neurological symptoms in Danes with a history of poliomyelitis: lifelong follow-up of late symptoms, their association with initial symptoms of polio, and presence of postpolio syndrome”. European Neurology 80 (2018): 295-303.
74. Darras BT. “Spinal muscular atrophies”. Pediatric Clinics of North America 62 (2015): 743-766.
75. Haziza M., et al. “Osteoporosis in a postpolio clinic population”. Archives of Physical Medicine and Rehabilitation 88 (2007): 1030-1035.
76. Nash MS and Bilzon JLJ. “Guideline approaches for cardioendocrine disease surveillance and treatment following spinal cord injury”. Current Physical Medicine and Rehabilitation Reports 6 (2018): 264-276.
77. Arens R and Muzumdar H. “Sleep, sleep disordered breathing, and nocturnal hypoventilation in children with neuromuscular diseases”. Paediatric Respiratory Reviews 11 (2010): 24-30.
78. Kidd D., et al. “Late functional deterioration following paralytic poliomyelitis”. QJM 90 (1997): 189-196.

Citation

Citation: Neetika Sharma. “Acute Flaccid Myelitis-A Narrative Review”. Acta Scientific Neurology 7.11 (2024): 60-68.

Copyright

Copyright: © 2024 Neetika Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.